|
AIDS Treatment News
Sculptra (Formerly New Fill) for Facial Wasting -- Where to Find Information on the Patient-Assistance Program
December 31, 2004 SculptraTM (marketed in some countries as New FillTM) was approved in August 2004 by the FDA "for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus." It was approved narrowly for this use because of the great need of many patients -- but the FDA wants to see more data before allowing its wider use for cosmetic purposes, where the need is not as great.
The product is expensive in the U.S. (about three times the price in Europe) -- in addition to the cost of doctors' services, which can vary greatly. It is important to find a physician who is well trained or experienced in its use. Dermik Laboratories (owned by Sanofi-Aventis), the company now selling Sculptra in the U.S., is setting up a patient-assistance program that will provide free or reduced-cost drug to patients who meet certain income and other eligibility requirements. It does not pay the doctors' bill, however. The key issue will be to get Sculptra covered by regular health insurance, like other reconstructive medicine. Some companies are refusing to pay for it by claiming it is "cosmetic." But many patients cannot maintain their job or career without the treatment. Information about Sculptra -- choosing a doctor, getting coverage through one's health insurance, or getting patient assistance if insurance is not available -- is changing rapidly:
You could also use a Google search, such as "Sculptra patient assistance" (without the quotes), or "Sculptra 2005" (also without the quotes) to locate recent articles. A background article by Bob Roehr in the Dallas Voice, published December 2004 or earlier, is at www.dallasvoice.com/articles/dispArticle.cfm?Article_ID=4418. Copyright 2004 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News. |